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EVALUATION OF THE EFFICACY AND LONG-TERM SAFETY OUTCOMES 
OF FIRST GENERATION DRUG-ELUTING STENTS IN OFF-LABEL 
INDICATIONS 
 
COREY SHEA 
 
 
ABSTRACT 
 
FDA approval of drug-eluting stents (DES) in 2002, was based on data 
obtained from several pivotal, short-term (< one year) randomized control trials 
that evaluated their efficacy in reducing in-stent restenosis when used in 
treatment of coronary artery lesions compared with bare metal stents (BMS). 
These trials excluded patients with complex coronary lesions. When the FDA 
approved use of DES in treatment of coronary artery lesions, the on-label 
indications only applied to a very limited subset of simple lesions. 
Immediate advantages of DES were observed in clinical practice for on-
label indications, specifically in their ability to significantly reduce in-stent 
restenosis after PCI. The increased short-term safety and efficacy seen in on-
label clinical cases soon led clinicians to expand the use DES to more complex 
lesions. These complex indications, not included in the pivotal FDA trials, are 
considered off-label. Off-label indications include bifurcation lesions, ostial 
lesions, lesions greater in length and diameter than those approved by the FDA, 
implantation in saphenous vein grafts, and lesions in the left main coronary 
artery. Currently, DES use for treatment of lesions presenting off-label indications 
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may comprise as much as 60% of clinical cases. However, early evidence that 
DES may play a role in adverse safety outcomes, has led many to question the 
use of DES outside their on-label indications. 
This paper sought to evaluate some of the current research investigating 
first generation DES use in four different off-label indications: coronary artery 
bypass graft lesions, saphenous vein graft lesions, ostial lesions, and chronic 
total coronary occlusions. In particular, it looked at studies, which compared the 
efficacy and clinical outcomes of DES and BMS treatment of each of the different 
lesion types. 
The results of this evaluation were very promising in that of the four 
specific off-label indications evaluated, all of them showed to be superior in 
reduction of neointimal growth and subsequent in-stent restenosis. Additionally, 
DES treatment of left main coronary artery lesions, saphenous vein graft lesions, 
and chronic total coronary occlusions showed to be superior in reducing the 
incidence rate of major adverse cardiac events and target vessel 
revascularization over various follow-up durations. The only scenario that DES 
did not prove to be superior to BMSs was the treatment of ostial lesions. 
Long-term randomized control trials with large study populations should be 
performed to further elucidate the effects of DES treatment of specific off-label 
lesions.  
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Introduction 
 
Coronary Artery Disease 
 Over one hundred years ago cardiovascular disease was responsible for 
less than ten percent of death around the world. With advances in medicine 
infectious diseases as one of the leading causes of morbidity has decreases 
causing the average age of the population to increase, and with it, the prevalence 
of cardiovascular disease. Currently, cardiac diseases account for 20-30% of 
deaths worldwide, and as much as 50% in developed countries, the majority of 
which are related to coronary artery disease (CAD).1,2 
 Coronary artery disease, also known as coronary heart disease (CHD), is 
a non-specific term that refers to a variety of pathologies resulting from either a 
partial or complete occlusion of the coronary vessels.3 The coronary arteries 
supply the heart, specifically the myocardium, with oxygenated blood. 
Development of atherosclerotic lesions in these vessels causes them to become 
stenotic, reducing blood flow to the heart, leading to symptomatic CAD and 
myocardial infarction (MI).2 
 While cardiovascular disease still remains a leading cause of death 
around the world, mortality rates in the United States have recently declined as a 
result of improved medical prevention and in-hospital treatment of patients with 
acute coronary pathologies. However, even with this current trend in the US it is 
expected that prevalence of chronic cardiovascular disease and mortality will 
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increase with expected increases in cardiovascular risk factors. Among these risk 
factors is hypertension, which affects more than 30% of the US adult population 
with another 31% being considered prehypertensive with an above normal blood 
pressure. These numbers are expected to further increase with population 
aging.4 Another major risk factor is Diabetes mellitus, which has been shown to 
be associated with a more than four-fold increase in death from CAD when 
compared to patients without the disease.5 The diabetic population is expected to 
jump from 171 million to 366 million worldwide between the years 2000 and 2030 
due to increasing population age and the obesity epidemic.6 Other major risk 
factors for CAD include cigarette smoking, cigarette smoking, and high 
cholesterol intake (Table 1).4 
  
Table 1: American Heart Association Guide to Risk Factors for CAD.4 
 
Major Independent Risk 
Factors 
Predisposing Risk 
Factors Possible Risk Factors 
Cigarette Smoking Physical Inactivity Fibrinogen 
Hypertension Obesity C-reactive protein 
Elevated total and LDL 
cholesterol 
Family History of 
premature CAD 
Homocysteine Elevated 
Lp(a) 
Low HDL cholesterol Ethnicity  
Diabetes mellitus Psychosocial Factors   
Older age   
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Atherosclerosis 
 The development of CAD was once thought to be the result an 
unavoidable narrowing of the coronary arteries. Recent investigation shows that 
stenosis actually arises from a much more complex process of plaque 
development with the potential to rupture and cause complete occlusion of the 
arteries leading to MI.4 The arterial wall is composed of three layers: the tunica 
intima, tunica media, and tunica adventitia. The innermost layer, the tunica 
intima, consists of an endothelial layer of cells protects the vascular wall and is 
responsible for regulation of cell proliferation and inflammatory and thrombotic 
processes. It deviation from normal endothelial cell processes in this layer that 
leads to the development of atherosclerotic plaques and coronary artery 
stenosis7. The currently accepted “Response-to-injury” theory suggests that 
atherosclerotic plaques develop in response to damage done to the endothelial 
layer of a vessel. Inflammation and healing processes occur in the body’s effort 
to heal the damage done to the artery, similar to healing of a wound. It should be 
noted, however, that although “injury” to the endothelium can be a physical 
forces, it is much more common that this damage from a biochemical stimulus. 
All of the aforementioned mentioned CAD high risk factors contribute to 
increased oxidative damage to the vessel. The generation of reactive oxygen 
species (ROS) have many effects, but two in particular that initiate the 
development of coronary artery stenosis. One effect is ROS react with nitric 
oxide (NO), which acts as a primary anti-atherogenic factor, diminishing its local 
 4 
availability. Additionally, ROS play a role in initiating signally pathways that 
stimulate the renin-angiotensin system (RAS), the endogenous endothelin 
system, and alter the activity of factors. All of these alterations cause the binding 
and infiltration of the endothelium by inflammatory cells.8 
The infiltrating monocytes develop into macrophages and begin to 
phagocytose low-density lipoprotein (LDL) and become foam cells, which 
undergo apoptosis. Further development of the plaque occurs when vascular 
smooth muscle cells (VSMCs) begin to proliferate from the tunica media into the 
intima where they secrete fibrous extracellular matrix encapsulating the 
accumulated lipids and other cells recruited to the area by the inflammatory 
pathways.7,8 Plaque development progresses with further remodeling of the 
fibrous cap that surrounds the lipid core, which continues to be infiltrated with fat 
and inflammatory cells. Over time the atherosclerotic lesion invades the lumen of 
the artery, occluding blood flow to the heart.7 
Clinically, it is important to understand the behavior of atherosclerotic 
lesions and their tendency to cause acute cardiac pathologies such as 
myocardial infarction.  While the size of a lesion and the extent to which it 
occludes a coronary artery has obvious significance, recent studies are 
particularly focused on plaque vulnerability rather than just size. Vulnerability is of 
particular importance because as the plaque develops it has the potential to 
ulcerate and rupture triggering pathways that causes thrombus formation and 
acute blockage of the artery.8 Current research has shown that ratio of lipid core 
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to fibrous cap size plays a key role in determining the vulnerability of 
atherosclerotic lesions. Specifically, lesions that have a large lipid core with a 
comparatively less prominent fibrous cap are more likely to rupture in comparison 
to similarly sized lesions with a higher content of smooth muscle and extracellular 
matrix development. Plaques made up of greater than 40% lipid are at higher risk 
for rupture. Similarly, plaques that cause myocardial infarction have been shown 
to have fibrous caps thinner than 60 µm. One final factor that appears to 
contribute to the vulnerability of atherosclerotic lesions is the level of 
macrophage, mast cell, neutrophil and activated leukocyte presence within the 
nucleus of the lesion. These cells secrete enzymes and tissue factors that break 
down fibrous matrix and stimulate pro-thrombotic events, which can lead to 
vascular occlusion and acute ischemic events.7 Figure 1 illustrates the 
morphology of stable, unstable and ruptured atherosclerotic plaques. 
 
 
Figure 1: Morphology of Stable, Unstable and Ruptured Atherosclerotic 
Plaques.4 
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Unfortunately, despite the strides made in understanding atherogenesis 
and the mechanisms responsible for lesion ruptures leading up to acute coronary 
events, it is still very difficult to predict how these events will present themselves 
in a clinical setting. A patient with no history of CAD could present with an MI, 
and go on with complete stability after the event. At the other end of the 
spectrum, patients often present with rapidly developing angina leading to an 
acute ischemic event, followed by chronic angina or new infarction within a few 
weeks or months. Further efforts are currently being made to investigate the 
mechanisms that are responsible atherosclerotic plaque rupture on both a local 
and systemic level. Currently, many biomarkers and their role in plaque instability 
as a systemic inflammatory process are being investigated in hopes of being able 
to better understand the clinical presentations of acute ischemic events and 
chronic CAD.7 
 
Percutaneous Coronary Intervention 
 While it remains one of the leading causes of mortality across the globe, 
dramatic improvements have been made in the treatment of coronary artery 
disease. Revascularization of coronary vessels affected by CAD was once done 
through highly invasive surgical procedures involving splitting of the sternum, 
otherwise known as “open-heart” surgery.9 While coronary artery bypass graft 
CABG surgery is still used in many revascularization scenarios, catheter-based 
percutaneous coronary interventions (PCI) involving balloon angioplasty and 
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coronary artery stent implantation have become a routine therapy for CAD and 
MI.9,10  
 Coronary angioplasty is a procedure first developed by Gruntzig in 1977 
as an alternative to CABG.10 The first PCI was performed using a catheter with a 
balloon at the tip. The balloon was inflated at the site of coronary stenosis in 
order to dilate the obstructed vessel. Balloon angioplasty was certainly a 
revolutionary development in revascularization procedures, but it has a major 
limitation in that the dilated portion of the artery has tendency to constrict during 
healing, a process called restenosis, which was found to occur in as many as 
40% of balloon angiography cases.10 To solve this problem, coronary stents were 
developed. Stents are metal, tubular, mesh devices that are placed over the 
balloon-tipped catheter in collapsed form and expanded at the stenotic portion of 
a diseased vessel. The stent acts as a mechanical scaffold, reducing the recoil of 
the arterial wall and allowing the vessel to remain open.2 While these bare metal 
stents (BMS) were shown to significantly reduce the rate restenosis and the 
number of repeat revascularization procedures, in-stent restenosis (ISR) rates 
still remained between 20-30% at follow-up between 6-12 months post 
implantation.11,12 In-stent restenosis is defined as a narrowing of the diameter of a 
stented vessel by at least 50%, and is caused by excess neointimal formation at 
the stent site, as opposed to elastic recoil of the vessel seen in restenosis during 
balloon angiography.2,12 
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 In 2002, the US Food and Drug Administration (FDA) approved drug-
eluting stents (DES), designed to answer the problem of in-stent restenosis seen 
in the BMS.9 Drug-eluting stents are typically comprised of a bare-metal stent, 
coated with a polymer responsible for carrying drugs, such as sirolimus 
(CYPHER) and paclitaxel (TAXUS), aimed at disrupting the cellular and 
molecular pathways responsible for in-stent restenosis.12 DES have proven to be 
far superior to the BMS in that they significantly lowered rates of ISR (to around 
5%) and necessary repeat revascularization procedures after the initial PCI. DES 
have also shown promising results for patients who have suffered an acute MI in 
that treatment with DES has been shown to significantly decrease mortality rates 
within 2 years of implantation when compared to bare metal stents.13 Although 
the results from early, randomized control trials that led to FDA approval of DES 
in clinical practice, one major drawback has been the long-term safety concerns 
associated with their use. Specifically, evaluation of clinical cases demonstrates 
that DES use may be the cause of late stent thrombosis (LST) and very late stent 
thrombosis (VLST) leading to acute ischemic events.10 Studies that investigate 
the clinical effectiveness and long-term safety concerns will be discussed in 
greater detail later in this paper. 
 When the FDA evaluated the first generation of drug-eluting stents for 
approval, they based their decision for commercialization on results of multiple 
randomized control trials. Data from these trials delineated reductions of IRS and 
the necessity for repeat revascularizations when compared with bare metal 
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stents, which was enough to warrant approval of DES use in clinical practice. 
Because many common clinical cases that generally present with more 
complexity were excluded from the early trials comparing BMS and DES, the 
FDA only considers a narrow spectrum of indications to be “on-label.”14 The on-
label indications for the first approved Sirolimus-eluting stent included de novo 
lesions no longer than 30 mm in native coronary arteries of between 2.5 and 3.5 
mm in diameter. However, CAD more often than not presents as a much more 
complex pathology than is covered by the on-label DES indications. In fact more 
than 50% of uses are considered off-label.14 Table 2 summarizes the criteria for 
FDA approved on-label use and frequent off-label indications for use of DES. 
Use of DES in off-label cases assumes that the effectiveness of this treatment in 
on-label scenarios carries over to more complex diseases processes. The validity 
of this assumption is still under much investigation, since these cases were not 
substantially represented in the pivotal trial populations. Safety and long-term 
adverse effects of DES use in complex CAD patients is still yet to be fully 
understood.14 
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Table 2: On-Label and Off-Label Indications for DES Use.14 
 
On-Label Indications Off-Label Indications 
Single lesion treated >1 lesion treated 
Lesion <30 mm in lenth Total stent length >36 mm 
Reference vessel diameter >2.5 mm 
and <3.75 Bifurcation Lesion 
Lesion in native coronary artery Coronary Artery Bypass Graft Lesion 
 Baseline creatine kinase MB >3 ULN 
 Maximum balloon diameter >4 mm 
 Chronic Total Coronary Occlusion 
 Ejection Fraction <25% 
 Left Main Coronary Artery Lesion 
 
 
Specific Aims and Goals 
Due to fact that data from randomized control trials investigating off-label 
DES use is limited, coupled with evidence that DES use may be associated with 
stent thrombosis, concerns about the long-term safety and efficacy of DES in 
these scenarios is a major concern. While there are some studies that have 
begun to evaluate the use of DES in off-label cases, comprehensive analysis of 
these situations is far from complete. A study by Win et al. (2007) compared the 
clinical outcomes of DES and BMS use in varying off-label situations.14 Their 
studied showed DES use might be associated with adverse effects. However this 
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study, along with others like it, have many limitations including the fact that they 
neglect to account for varying degrees of complexity amongst different lesions.14 
The goal of this paper is provide an evaluation of clinical outcomes and 
safety concerns associated with off-label first generation DES use in a lesion 
specific manner. Due to the fact that different subsets of coronary artery lesions 
vary in complexity it is not effective to compile them all into one category. This 
paper plans to examine recent studies that compare the efficacy and safety of 
DES and BMS use in treatment of left main coronary artery lesions, saphenous 
vein graft lesions, ostial lesions, and chronic total coronary occlusions. Obtaining 
data for use of off-label indications in a case-by-case manner could be very 
helpful in making treatment decisions in a clinical setting. Additionally, this study 
plans to point out some of the limitations of current research in hopes of guiding 
future research efforts on the use of drug-eluting stents. 
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Drug-Eluting Stents 
 
Design 
 Before discussing their use in clinical settings it is important to examine 
the basic design of drug-eluting stents. The design of the stent is critical for 
ensuring that, once implanted, it is able to maintain patency of the vessel while 
also effectively delivering the desired drug to the vessel wall and not drastically 
compromising the normal function of the vessel.12 Most first generation stents 
have either a modular or slotted-tube design, and are made from inert metals, 
usually stainless steel. However, recent technological advances have led to 
some stents being made from metallic alloys, which allows for thinner struts with 
increase in strength.2 They must also be collapsible, as to fit on the tip of a 
balloon-tip catheter and through arteries during angiography. When the stent 
expands it must exhibit minimal shortening and conform to the inner wall of the 
vasculature without deforming the vessel. Currently, both SES and PES drug 
eluting stents have closed cell, slotted tube design with sinusoidal struts, joined 
by flexible, N-shaped link segments (Figure 2).12 Due to long-term safety 
concerns, specifically stent thrombosis (discussed in the next section), 
associated with first generation DES, a lot of current research is ongoing in an 
effort to evaluate stent structure and the role it plays in clinical pathologies.12 
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Figure 2: Taxus Express PES.12 
 
 Since the purpose of the drug-eluting stent is to deliver a drug to the local 
environment of the coronary lesion, the drug must be loaded on to the stent and 
released in a controlled manner. The most common method of loading the drug 
onto the framework of the stent, in current practice, is to coat the metal with a 
thin layer of permanent, synthetic polymer, which has been pre-loaded with a 
specified concentration of the desired drug. Pre-loading of the drug is performed 
by mixing the drug with the polymer so that it becomes “trapped” in the polymer 
matrix. Once the stent has been implanted in to the vessel the drug is released 
by simple diffusion. The type of polymer used regulates diffusion rate. Obviously 
the polymers used to should, ideally, be biologically inert so that it does not 
trigger a thrombotic or inflammatory pathway.12 The types of drugs used in first 
generation DESs and their intended mode of action is discussed later on in this 
section. 
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Stent Thrombosis 
Much debate and research has gone into investigating whether or not 
long-term safety concerns associated with the use of DES are valid. While first-
generation drug-eluting vascular scaffolds like the sirolimus-eluting stent (SES) 
and paclitaxel-eluting stent (PES) have exhibited major strides towards reducing 
ISR and target lesion revascularization (TLR) when compared to bare metal 
stents, the primary concern today is their association with late LST and VLST.15 
Late stent thrombosis is considered any thrombus that occurs between 30 days 
and one year post PCI, while late stent thrombosis is any thrombus occurring 
later than one year post implantation.16 In 2007, the Academic Research 
Consortium recommended standardized definitions of stent thrombosis. These 
standardized definitions were adopted and used in a meta-analysis of eight 
different clinical trials that investigated the long-term follow-up of patients 
receiving treatment with SES and PES. Analysis showed that occurrence of 
VLST was significantly higher in cases treated with DES compared with BMS. 
Interestingly, and contrary to findings from earlier studies, prior to having the 
standardized definitions of LST and VLST, this meta-analysis found no difference 
between DES and BMS rates of LST. Further evaluation by other studies has 
since supported these findings.12 
Although their use is relatively new to clinical practice, recent studies have 
more thoroughly examined some of the longer-term outcomes of patients treated 
with DES. Wenaweser et al. looked at a total of 8,146 patients who underwent 
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PCI with either SES or PES from the Bern-Rotterdam registry for a follow-up 
period of four years.17 The cumulative incidence of definite stent thrombosis at 
the end of four-year follow-up was 3.3%. Additionally, the cumulative incidence of 
occurrence of probable and definite stent thrombosis was 5.7%. Interestingly, the 
annual occurrence of stent thrombosis increased at a steady 0.53% (between 0.4 
and 0.6 annually) up to four years post PCI.17 A more recent study has 
corroborated the Bern-Rotterdam registry data. Sarno et al. performed a follow-
up of 21,717 patients in the Swedish Coronary Angiography and Angioplasty 
Registry (SCAAR).18 Results of this study showed an annual rate of stent 
thrombosis of 0.50% and a cumulative incidence of definite thrombosis of 1.3% 
during a two-year follow-up period.18  
 
Vascular Responses to Drug-Eluting Stents 
Very late stent thrombosis has had an overshadowing effect on DESs and 
the enthusiasm generated around their ability to reduce the rate of ISR and TLR. 
Understanding the mechanism of DES and their effect on the arterial wall is of 
paramount importance when it comes to determining whether DES or BMS is the 
best treatment option, especially in off-label indications. As previously mentioned, 
DESs were designed to combat the problem of in-stent restenosis seen in BMS. 
Both first generation DES, SES and PES, rely on the same approach of 
delivering antiproliferative drugs to the endothelium to inhibit neointimal growth. 
In doing so, both drugs also have an inhibitory effect on endothelial regrowth. 
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Sirolimus has also been linked with impairing growth and differentiation of 
endothelial stem cells, though whether or not this leads to endothelial dysfunction 
in atherosclerotic lesions is still unknown.19 
SES and PES, the primarily used first-generation DES, both achieve 
reduction of restenosis by disrupting different molecular pathways involved in 
VSMC proliferation. Sirolimus is designed to disrupt mTOR, the target of 
rampamycin, and prevents the degradation of a cyclin-dependent kinase inhibitor 
involved in smooth muscle cell growth and differentiation in the arterial wall. 
Additionally, it deacitivates p70 S6 kinase pathway activity, an key regulatory 
step in the cell cycle response to growth factors, leading to stunted endothelial 
cell development.19 
Similarly, paclitaxel acts to suppress endothelial and smooth muscle cell 
proliferation and migration to the vascular wall by interrupting microtubule 
function during mitosis. Interestingly, unlike sirolimus, paclitaxel also causes 
significant fibrin deposition as well as macrophage infiltration. At higher 
concentrations arterial wall breakdown occurs and smooth muscle cell depletion 
occurs. All of these factors may play a significant role in causing stent thrombosis 
especially since increased macrophage concentration could lead to an 
inflammatory response.19 
The delayed healing of the endothelial lining in coronary arteries seen with 
these first generation DES is of paramount importance to understanding the 
association between DES and stent thrombosis. In addition to acting as a simple 
 17 
structural lining to the coronary vessel, endothelial cells also provide the 
vasculature with regulatory factors for mediating thrombotic cascades. One study 
using cultured endothelial cells showed that sirolimus and paclitaxel exhibited 
increases in plasminogen activator inhibitor (PAI)-1, which is involved in 
regulating the clotting cascade.20 Interestingly sirolimus’ inhibition of mTOR also 
indirectly contributes to a local prothrombogenic and proinflammtory environment 
surrounding the stent. Inhibition of this target increases thrombin and tumor 
necrosis factor (TNF)-α expression in the endothelial cells. In addition to 
increased macrophage infiltration, paclitaxel also activate c-Jun NH2-terminal 
kinase, an important signaling molecule for monocyte regulation of the 
proinflammatory environment. Dysfunction with anti-thrombotic pathways, in 
conjunction with evidence that both types of DES enhance a local 
proinflammatory environment, greatly enhances the risk of thrombosis.19 
Delayed endothelial growth and dysfunction may only be one of the many 
factors leading to late stent thrombosis, Finn et al. note that none of the cases 
examined demonstrating LST had complete endothelialization.19 Otsuka et al. 
examined 46 human autopsy cases exhibiting 62 separate coronary lesions 
treated with first generation DES for longer than 30 days. Stent thrombosis had 
occurred at 28 of these lesions. In their study they looked at stent strut coverage 
as a means of evaluating the amount of endotheliazation. Results showed that in 
the DES lesions, the mean number of struts, the ratio of uncovered struts to total 
struts per section and the average stent length without neointimal coverage were 
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all greater in thrombosed lesions than the non-thrombosed lesions. These 
findings further support the notion that DES targeting of neointimal growth may 
directly play a role in stent thrombosis. Furthermore, they observed that the 
distance between struts in thrombosed lesions was significantly less than in non-
thrombosed lesions, and that in sections where average strut distance was lower 
there was less endothelial coverage of the stent. Decreased endothelial growth 
may be a function of local drug concentration and since the drugs are loaded 
onto the struts of the stent, shorter distances could lead to higher local 
concentrations. Also since the sirolimus and paclitaxel are lipophilic drugs, their 
retention and local concentration can be greatly affected by the differences in 
plaque morphology.15 These differences in plaque morphology and disease 
progression are an extremely important consideration, especially extrapolating 
the efficacy and safety of on-label DES use to their use in off-label cases. 
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Off-Label Use 
 
FDA approval of first generation drug-eluting stents was based on results 
from randomized clinical trial with short-term follow-up (<1 year). These trials 
showed extremely promising results in terms of drug-eluting stents’ ability to 
reduce in-stent restenosis and target lesion revascularization in the coronary 
arteries without increases in adverse cardiac events often seen in bare metal 
stent use. These trials, however, were limited to, from a clinical perspective, 
uncomplicated coronary artery lesions (Table 2) and were not designed evaluate 
long-term safety concerns like stent thrombosis.19 The advantage of on-label 
DES use was almost immediately accepted and their clinical use quickly 
expanded to applications outside of the FDA approved situations.21 Due to the 
complexity of CAD in real-world practice, coronary lesions cannot be classified 
within the originally approved criteria more often than not. Because of this off-
label applications such as DES implantation in the left main coronary artery 
(LMCA), bifurcation lesions, ostial lesions, chronic total occlusions, in-stent 
restenosis, severely calcified lesions, lesions of unapproved length, saphenous 
vein grafts, and use in cases of acute MI, all of which are “off-label,” comprise 
about 60% of uses in today’s practice.19,21 Effectiveness and long-term safety of 
off-label DES remains a major concern because of the increasing complexity that 
these lesions occur in comparison to the approved indications. While some early 
studies suggest that there are adverse effects and reduced efficacy associated 
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with off-label use, very little research has compared DES and BMS in specific 
lesion types to provide a more comprehensive insight into off-label outcomes.21 
The following sections will take a more in-depth look at current research aimed at 
investigating first generation DES use in specific off-label indications and their 
clinical outcomes when compared with BMSs. 
 
Left Main Coronary Artery Lesions 
The left main coronary artery supplies as much as three-quarters of the 
heart with oxygenated blood. This means that when this vessel becomes 
occluded patients are usually symptomatic and at risk of major adverse 
cardiovascular events, which include acute myocardial infarction and death.22 
Traditionally, CAD in this vessel has been treated with coronary artery bypass 
surgery. PCI with DES is usually indicated in cases where the patient is at a high 
risk for surgical complications or is affected by other advanced pathologies such 
as chronic obstructive pulmonary disease (COPD).23 
Not long after the FDA approval of DES did researchers begin looking at 
their efficacy in treating LMCA stenotic lesions. One of the first studies to 
compare the outcomes of DES to BMS in LMCA lesions was published in 2005. 
In this study Seung-Jung Park et al. observed 102 patients who received elective 
implantation of SESs for treatment of de novo LMCA lesions showing 
symptomatic disease or greater than 50% diameter reduction during 
angiography.24 This group was compared to 121 control-group patients who 
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received BMS for the same inclusion criteria. Periprocedurally, there were no 
incidents of MACE, stent thrombosis, or the need for emergency CABG surgery 
in either group. Similar to the clinical trials that lead to the FDA approval for on-
label use, at 6-month follow-up patients who received treatment with SES 
exhibited significantly lower ISR, compared to the BMS control group (7.0% 
versus 30.3%, p<0.001). Even more promising were the results at 12-month 
follow-up, which showed freedom from MACE (death, myocardial infarction, and 
TLR) was significantly higher in cases using SES compared to BMS (98.0 ± 1.4% 
versus 81.4 ± 3.7%, p = 0.003, Figure 3). There were no deaths or MI in either 
group, but two and 22 TLRs in the SES and BMS control groups, respectively.24 
 
 
Figure 3: Kaplan-Meier curves for one-year MACE-free survival rates in 
patients treated with SES and BMS for LCMA Lesions. Figure taken from 
Park et al. (2005).24 
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The results of this early study are certainly promising in that they show the 
success of SES in treating LMCA lesions without any incidence of adverse 
effects at one year. Moreover, comparison of the baseline characterization of the 
lesions in each group showed that lesions treated with SES were more 
pathologically complex in that they exhibited more multivessel involvement, 
bifurcation lesions and longer lesion length on average. Other studies up to this 
point, specifically reports from the RESEARCH registry, had suggested favorable 
clinical outcomes with DES use in LMCA lesions. However, the study by Park et 
al. was one of the first with enough cases to demonstrate statistical power.24 One 
major limitation of this investigation, however, is that it only followed patients up 
to one year after implantation. While this does provide insight into the occurrence 
of LST after DES use, it does not allow us to evaluate the long-term safety 
concerns. 
More recently, Kubo et al. presented data from a study that followed 250 
patients who received LMCA lesion treatment with DES from 2003 to 2005 for 
seven years after stent implantation and compared them to BMS patients.25 
Results from this study showed that the incidence of death and MI was similar 
between both stent groups while the incidence of TLR at seven-year follow-up 
was significantly less in the DES group compared to the BMS group. Specifically, 
TLR was significantly lower in years one through four in the DES group, and 
similar between both groups between years four and seven.25 This study 
reaffirms the results seen in the study by Park et al. (2005) showing that there 
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was no increased MACE risk associated with DES treatment of LMCA stenosis, 
while having the added benefit of reducing TLR. The obvious advantage to this 
later study is that it provides a better insight into the long-term efficacy and safety 
concerns by having a much longer follow-up than the original study. 
 
Saphenous Vein Graft Lesions 
 Saphenous vein aortocoronary bypass grafts (SVG) are used in almost all 
CAPG surgeries.26 The saphenous vein is a long, superficial vein found in the leg 
that is used as the conduit for revascularization in bypass surgeries described in 
the previous section.27 SVGs, unfortunately, are associated with a high rate of 
failure and often need to be revascularized by PCI or another CABG. However, 
due to the fact, that repeat CABG is more difficult than the original CAPG, stent 
placement in SVG lesions has become intervention of choice in clinical 
situations.26 Because of the high failure rate of SVGs, as much as 10% of all PCI 
procedures are done on these graft lesions, yet, because of their poor 
representation in the early pivotal trials of DESs, they are still considered an off-
label indication.28 
While bare metal stents have proven to be more effective than the original 
balloon angiography interventions, there is a significantly higher risk of restenosis 
associated with their use in SVG lesions than in native coronary artery lesions. 
The development and early of success of DESs in reducing ISR, has been 
particularly exciting for SVG lesions. However, several factors make SVGs more 
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than native coronary arteries making it very difficult to anticipate whether the 
effects of DESs can be extrapolated. The progression of the atherosclerotic 
process, the mechanism of ISR with more thrombosis, and increased rate of 
plague progression are all characteristics of SVG vessels that make them more 
pathologically complex.26,28 
As of 2008 there had been five retrospective studies that evaluated the 
use of DESs in treating SVG lesions in comparison to BMSs.26 Collectively, these 
studies evaluated the major adverse cardiac events, ISR, TLR and target vessel 
revascularization (TVR) for an intermediate-term (6-12 months) follow-up. 
Results from four of the five studies showed that, when compared to BMS 
implantation, use of DESs showed significant reduction in the incidence of MACE 
(including MI) at both six- and twelve-month follow-up.29–32 Furthermore, the 
study by Ge et al. demonstrated that DES implantation significantly lowered the 
incidence of ISR, TLR, and TVR up to six months.29 Only one retrospective study 
performed before 2008 did not show significant reduction in MACE. Chu et al. 
found no statistical difference in the incidence of clinical events in 48 DES and 57 
BMS treated lesions at one-year follow-up (21% vs 18%, respectively, p = 
0.84).33 
There are several drawbacks to these retrospective studies. The first is 
that each of them used a small number of cases, which yields a limited amount of 
data. Secondly, two of these studies only had a six-month follow-up period, while 
the other three only followed for up to one year. As described earlier, many of the 
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adverse effects believed to be associated with DES use often happen further 
from the time of stent implantation than one year. To obtain a more 
comprehensive picture of SVG PCI effectiveness longer follow-up time is a 
necessity. Lastly, these are only retrospective studies. To be able to better 
understand the statistical validity of the difference seen in clinical outcomes, 
randomized controlled trials need to be performed. 
Mehilli et al. (2012) were one of the first to compare first generation DES 
and BMS treatment of SVG lesions in a multicenter randomized controlled trial 
powered for clinical endpoints.28 Their study included 303 patients receiving DES 
treatment and 307 patients receiving BMS (610 total patients), and examined the 
combined incidence of MACE at a one-year follow-up. Thirty patients were lost at 
one-year follow up without any significant difference between the DES and BMS 
groups (15 DES patients, 15 BMS patients; p = 0.97). The incidence of the 
primary endpoint of death, MI, or TLR was lower in DES group (44 patients 
versus 66 patients for BMS), but this was mainly due to difference in TLR, not 
death or MI. There was no significant difference in the number of deaths or 
incidence of MI between the DES and BMS groups (15 versus 14 respectively). 
The incidence of TLR was 19 in the DES group and 37 in the BMS group, 
indicating almost a 50% reduction. This was largely attributed to the drug-
induced effect on the endothelial layer at the molecular level seen during 
angiographic follow-up in about two-thirds of the cases. Results from this trial are 
summarized in Figure 4.28 
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Figure 4: One-year Cumulative rates of outcomes in patients assigned to 
receive DES or BMS for SVG lesions. Kaplan-Meier Curves shown for (A) the 
primary composite endpoint (composite death, MI, TLR); (B) the secondary 
endpoint of TLR; (C) secondary endpoint of all-cause death; and (D) combined 
endpoint of death or MI. HR=Hazard Ratio. Figure taken from study by Mehilli et 
al. (2011).28 
 
 
 
The results from this multicenter randomized control trial are promising in 
that they corroborate data from the previous retrospective analysis. Despite 
greater complexity usually associated with SVGs and the concern that DES 
efficacy in on-label indications not being transferable to this specific off-label 
scenario, their use in this trial indicate superior efficacy compared to BMS. 
Restenosis and failure of SVGs are a major limitation of using SVG to treat 
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LMCA disease. Significant reduction of restenosis associated with drug-eluting 
stent treatment in these trials could play a prominent role in clinical decision 
making of treating diseased grafts, especially considering the complications of 
repeat CABG surgeries.28 One additional finding from the randomized control trial 
worth noting is that there was no difference in the occurrence of definite or 
probable stent thrombosis seen between two groups. As a matter of fact, the 
number of incidences was actually less in the DES group than in the BMS group 
(three versus five, respectively).28 This is of obvious significance due to the fact 
that stent thrombosis a primary long-term safety concern of DES use in off-label 
scenarios. However, clinical follow-up of more than one year should be done to 
see if this trend continues for a longer duration. 
 
Ostial Lesions 
The next type of off-label coronary lesion that will be examined are ostial 
lesions. In particular one multicenter prospective observational study comparing 
DES and BMS treatment of ostial lesions and the results from a lesion specific 
meta-analysis will be evaluated. The coronary ostia are the regions where the left 
and right main coronary arteries originate from the ascending aorta just above 
the aortic valve. An ostial lesion is classified as an atherosclerotic plaque that 
develops at the origin of a coronary artery.34 These specific types of lesions are 
one of the more pathologically complex confronted in CAD. They are usually 
associated with a higher degree of plaque calcification, varying blood flow 
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patterns at the region of the lesion, and increased elastic recoil from the wall of 
the aorta. However, despite these added risks, as many at 20% of cases 
receiving treatment for off-label coronary vessel disease indications are for ostial 
lesions.34 
The first study to be examined was performed by Vasaiwala et al. (2012) 
and compares the treatment outcomes of ostial coronary lesions with drug-
eluting stents and bare metal stents for a three-year follow-up period.34 This 
study took a multicenter prospective observational approach and performed 
follow-up at one month, six months, and then at one, two and three years post-
PCI. They looked at death, MI and repeat revascularization procedures as clinical 
end points at each follow-up. Treatment of 464 ostial lesions was attempted with 
BMS and 351 lesions with DES. There was no significant difference in the 
location or vessel diameter where lesions occurred. After completion of three-
year follow-up the incidence of clinical endpoints were not different at statistically 
significant level. BMS treated lesions showed higher rates of death, while DES 
treated patients showed higher rates of MI and repeat revascularization. While 
not related to the long-term safety, it should be noted that periprocedural in-
hospital death was significantly higher in BMS implantation, while all other MACE 
showed no statistical differences at this time point.34 
The results from this study are similar to those found in a lesion-specific 
meta-analysis, performed by Beohar et al., of four reports evaluating clinical 
endpoints associated with DES treatment of ostial lesions. The four included 
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studies collected outcomes of death, MACE, MI, TLR, and thrombus at six- to 12-
month follow-up and incidence of MI at three-years.21 Rates of death, stent 
thrombosis, and TLR were not significantly different between patients receiving 
DES and BMS treatment at six- to 12-month follow-up, corroborating findings 
from Vasaiwala et al.21,34 Unfortunately, no data on the incidence of MI in BMS 
cases was collected in any of the included reports, leaving statistical comparison 
to DES cases impossible.21 
 
Chronic Total Occlusions 
 The final off-label indication that will be evaluated here is the use of drug-
eluting stents in chronic total coronary occlusions. Specifically, the randomized 
Primary Stenting of Totally Occluded Native Coronary Arteries (PRISON) II study 
and case-control study published by De Felice et al. in 2013 will be examined. 
  Before the PRISON II study was performed, no randomized control trials 
had been conducted to gather data on the effectiveness of DES in chronic total 
coronary occlusions (CTO).35 In this trial, 200 patients were randomly assigned to 
receive either BMS treatment or SES treatment for CTO. Angiographic restenosis 
was the primary end point of the study, with a number of secondary end points, 
which included MACE. Unfortunately, this randomized control trial only had a six-
month follow- up term. Results did show that the sirolimus-eluting stent group did 
show significantly lower rates of angiographic restenosis, TLR and all major 
MACE at six-month follow-up.35 With such a short follow-up period, however, it is 
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difficult to use the results of this study in clinical practice, especially when it is the 
long-term safety and efficacy of off-label DES use that is of paramount concern. 
 De Felice et al. investigated the persistence of the superior efficacy of the 
DES treatment of CTO, demonstrated in the PRISON II trial, at five-year follow-
up. Their study consisted of 315 (298 data points collected due to 17 lost post-
PCI) patients who underwent successful CTO PCI. Only patients who had 
occlusion of a native coronary artery for longer than three months were eligible 
for inclusion. Of the 315 patients, 156 received implantation with either paclitaxel- 
or sirolimus-eluting stents and 159 patients received BMS implantation. The 
endpoints included MACE (death and MI) and TLR, which were collected at one, 
three and five years post-procedure.36 
 As previously mentioned 298 of the original 315 patients in the study 
completed the five-year follow-up term. At one-year post-PCI, the incidence rate 
of MACE was significantly lower in patients treated with DES compared to BMS 
(2% versus 20%). The rate of incidence of TLR was also significantly lower in 
DES patients. At three-year follow-up MACE (23% for BMS versus 8% for DES) 
TLR incidence rates (20% for BES versus 6% for DES) were still significantly 
lower DES patients. At five-year follow-up, DES continued to show significantly 
reduced incidence of MACE when compared to BMS (15.6% versus 31%, 
respectively. Additionally, TLR incidence rates were still lower in DES (8%) when 
compared to the BMS group (33%). In addition to looking at MACE and TLR 
endpoints, the researchers also collected data on stent thrombosis over the five-
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year period and found that stent thrombosis occurred in 12 patients with six 
definite VLST cases in the DES group. While there was no statistically significant 
difference between DES and BES stent thrombosis, there was a marked 
increase in the DES group compared to the BES group, which had seven stent 
thrombotic events and three LST events.36 
 Despite the fact that this was a case-control study and not a randomized 
control trial, the results found by De Felice et al. provide some very valuable 
insight into DES use for CTO in clinical practice.36 The five-year follow-up term 
provides a much better look into long-term efficacy of the PCIs. Drug-eluting 
stents use in this study showed superiority when compared to bare metal stents 
in reducing the incidence adverse clinical outcomes when, making a strong case 
for their use in this particular off-label indication. One alarming finding of the 
study, however, was the fact that stent thrombosis, and in particular VLST, was 
higher than in the BMS group. Although the rate of restenosis was not 
significantly different between the two treatment groups, six cases of VLST were 
found in the DES group compared to zero in the BMS group. As described in 
previous section, increased incidence of LST and VLST in the use of drug-eluting 
stents in both on- and off-label situations is a prominent concern. This makes this 
finding particularly concerning.36 
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DISCUSSION 
 
Conclusions 
 Since their approval by the FDA in 2002, drug-eluting stents have proven 
to be superior to bare metal stents, especially in reduction of in-stent restenosis 
and the need for target lesion revascularization.14 The pivotal trials that led to the 
approval of DES, however, excluded patients with complex lesion pathology. This 
led to the approval of DES use in only simple coronary lesions presenting with a 
small range of characteristics. These indications are known as the on-label 
indications. Due to the immediate recognition of DES’ efficacy in limited in-stent 
restenosis, their use in complex, off-label indications become common in clinical 
practice. Some estimates show that off-label use may account for as much as 
60% of all DES PCIs.21 However, because the pivotal FDA trials only evaluated 
efficacy of simple coronary lesions in a short-term follow-up period, the long-term 
efficacy and safety of DES in off-label situations have been a primary concern. 
To date, some research has shown that DES use has been associated with stent 
thrombosis, which can lead to MACE like death and MI. Little clinical data exists 
evaluating the long-term clinical outcomes of DES use in off-label indications in a 
lesion-specific manner. 
 This particular study sought to evaluate some of the current research 
investigating first generation DES use in four different off-label indications: 
coronary artery bypass graft lesions, saphenous vein graft lesions, ostial lesions, 
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and chronic total coronary occlusions. Evaluating the treatment outcomes in a 
lesion-specific manner is much more valuable in a clinical setting because it 
allows for a more focused insight when making treatment decisions on a case-
by-case basis. Stenotic lesions, more often than not, come with varying degrees 
of complexity and comorbidities. Research that puts all off-label indications into 
one category is too broad and does not allow for the identification of problems in 
specific scenarios. As some of the current research has shown, DES use in 
some off-label situations is much more effective and safe than in others. 
 This evaluation of some of the current investigation of the effectiveness of 
first generation drug eluting stents in various off-label situations led to some 
interesting findings. Data from the lesion specific studies that we found 
comparing first generation DES to bare metal stent uses all corroborated data 
from the pivotal FDA trials that showed incidence rates of ISR were significantly 
diminished in DES groups when compared to BMS groups, in all four off-label 
lesion types. This reduction was expected because both sirolimus- and 
paclitaxel-eluting stents are designed to target pathways that lead to neointimal 
growth at the endothelial layer of the vasculature. The magnitude of reduction in 
these trials has been shown to be as much as 50-70% when compared to 
BMSs.28 While the efficacy of DESs in reducing neointimal growth in off-label 
situations is not really at question it is important to point out that their efficacy is 
not reduced in these situations. 
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 With regards to the incidence of major adverse cardiac events, included 
death, MI, and the need for target lesion revascularization, the studies we 
evaluated actually showed that, contrary to initial concerns, use of DESs in 
treatment of off-label lesion indications did not result in increased rates of 
incidence when compared to BMS treatment. In fact DES use in left main 
coronary artery lesions, SVG lesions and CTOs appeared to be superior to BMS 
use. In LMCA lesions DES treatment, Park et al. (2005) showed that freedom 
from MACE was significantly lower when compared to BMS treatment, with no 
incidence of death or MI at one-year follow-up.24 Even more promising was data 
presented by Kubo et al., which showed that the incidence of TLR in these types 
of lesions was still lower in DES treatment at significant level through seven-year 
follow-up.25 This seven-year follow-up study is of particular importance because it 
is one of the first to show the long-term outcomes of LMCA treatment with DES 
implantation. This demonstrates that DES is a superior treatment choice over 
BMS for this type of lesion without risk of diminishing patient safety. 
 Treatment of SVG lesions has proved to be complex due to differences in 
disease progression when compared to native coronary arteries. These 
differences have made clinicians weary about safety of DES use in these types 
of lesions. We examined a report that summarized the results of five 
retrospective studies comparing DES and BMS treatment of SVG plaques. Again 
DES proved to significantly reduce the level of ISR and MACE at both six- and 
twelve-month follow-up. Results from a randomized control trial by Mehilli et al. 
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(2012), also showed similar results at one-year follow-up. Although these studies 
did not look past one-year post-PCI, the advantage of having data from a 
randomized control trial should not be undervalued. This trial was one of the first 
incidences in which differences in lesion pathology were accounted for by subject 
randomization, which further solidifies the data that shows that DES treatment of 
SVGs is superior to BMS treatment.28 
 Similar results were found in the incidence rates of MACE with DES 
treatment of CTOs. Again, results showed significant reduction in the rates TLR 
and MACE in DES treated lesions at six-month follow-up in the PRISON II trial.35 
These findings were further corroborated by De Felice et al., whose case-control 
study showed that DES treatment was superior to BMS use at one-, three- and 
five-year follow-up.36 The longer follow-up term provides valuable insight into the 
safety of DES use in this situation. One concern that arose from this study 
however was the increased incidence in stent thrombosis seen in DES patients. 
Although there was no statistically significant difference in the occurrence of stent 
thrombosis throughout the five-year study, six of the DES patients exhibited 
occurrence of VLST compared to zero cases in BMS patients.36 Since stent 
thrombosis is of paramount concern when considering the use of DES treatment, 
randomized control trials with long-term follow-up and enough patients to 
demonstrate statistical significance should be performed to provide see if stent 
thrombosis is a legitimate concern in treatment of chronic total occlusions. 
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 Of the four off-label lesion indications evaluated in this paper, ostial 
lesions were the only type in which DES treatment demonstrated clinical 
superiority compared to BMS. At three-year follow-up patients treated with DES 
and BMS showed similar rates of death, MI and repeat revascularization 
procedures at the target vessel. Of the four coronary lesion types examined, 
ostial lesions are usually the most pathologically complex, which may contribute 
to the findings that DES and BMS treatments were similar. Higher degree of 
plaque calcification, varying blood flow patterns at the lesion site, and increased 
vascular recoil at the lesion site are several characteristics that make PCI of 
ostial lesions increasingly difficult.34 Increased lesion complexity in these cases 
was evident in the research seeing as how rate of successful stent implantation 
was much lower in ostial lesion PCI procedures compared to the other studies 
that were evaluated. Intrinsic lesion complexity probably caused problems in both 
stents, leading to similar outcomes. 
 A look at several current, lesion-specific studies shows that the concern 
over adverse clinical outcomes in off-label drug use may be somewhat 
overestimates. While this is only a preliminary review of some of the data that 
compares DES use to BES use in treatment of coronary lesions, results show 
that DESs may be clinically superior to BMSs in SVG lesions, LMCA lesions and 
CTOs in reducing in-stent restenosis and decreasing incidence of MACE. While 
ostial lesion treatment with DESs and BMSs showed no significant difference it is 
reassuring to know DES did not increase the risk of MACE in these patients. 
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Observations made in the studies presented in this paper, are far from complete, 
but they could be very valuable towards guiding research into lesion-specific 
outcomes in future clinical trials. 
 
Limitations 
 A lot of the limitations of this paper are largely due to limitations in the 
studies that were evaluated for the different off-label indications. Firstly, there 
were very few randomized control trials that compared the efficacy of drug-
eluting and bare metal stents. In this paper only a total of two randomized control 
trials were presented. The advantage of randomized control trials, especially 
when comparing cases in clinical situations, is that they randomize which 
patients will be allotted into the different treatment groups, which eliminates 
baseline differences in patient characteristics. To give an example, in the study 
by Park et al. (2005) comparing DES and BES treatment of LMCA lesions, 
patients in the SES group were found to have more advanced disease 
progression than those in the BMS group. These differences included more 
multivessel coronary artery disease, more bifurcation lesions, longer lesion 
length, and smaller reference diameter. All of these characteristics could have a 
significant confounding effect on the clinical outcomes observed in the treatment 
group.24 
 Another limitation of the studies presented here was the duration of follow-
up. As mentioned, one of the main concerns with DES treatment is the long-term 
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safety of these devices when implanted in off-label situations specifically with 
regards to late and very late stent thrombosis. A lot of the studies included in this 
paper, and many that were excluded, only followed patients for a six-month or 
one-year period. The obvious limitations of these studies are that they do not 
follow patients for enough time to gain comprehensive insight into the long-term 
treatment outcomes. In real world clinical situations it is of paramount importance 
for treatment of CAD to have a lasting clinical effect. It has been well established 
already that DES are superior to BMS in reduction of short-term outcomes like in-
stent restenonsis. A lot of the current studies fail to follow patients for a long 
enough duration to have a clinical significance. 
 One of the limitations of this paper is that it is not entirely comprehensive. 
Only four of the off-label indications for drug eluting stents were chosen for 
evaluation. Decision to do so was based on several factors. One was that these 
off label situations were very commonly encountered in clinical practice. The 
second was that at least some long-term data was obtainable for these off-label 
indications. Many of the off-label indications that were excluded had data of 
treatment with a follow-up period of six months or less, which was deemed too 
short to have relevance in this evaluation. Finally, these four off-label scenarios 
were chosen because there was research that directly compared DES use to 
BMS use in each of these situations. While many studies looked at DES use in 
other off-label indications, they often times compared the efficacy of two different 
DES or looked only at DES in their analysis. 
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 Another limitation of this paper is that it only looked at the efficacy and 
long-term clinical outcomes of first generation drug-eluting stents, specifically 
sirolimus- and paclitaxel-eluting stents. Currently, there are second and third 
generation devices that use different drugs and stent platforms which are being 
used in trials that have shown promising results in eliminating some of the safety 
concerns with earlier stents.12 However, because most of the research 
investigating use of these drug-eluting stents is in relatively early phases, they 
were excluded from this paper. 
 One final limitation of this study is that we did discuss the use of anti-
clotting medication post PCI. Due to the fact that many studies had a high level of 
difficulty evaluating compliance with drug therapy after discharge from the 
hospital, data collection was far too inconsistent to be considered in this paper. 
However, this is certainly an area of future research that should be evaluated. 
 
Future Directions 
 In continuance of what has been observed in this paper, future research 
should focus on performing randomized control trials of different off-label 
indications that are commonly encountered in clinical practice. These trials 
should include a large population of patients to have enough statistical power to 
allow results to be significant. Additionally, these trials should have a long-term 
follow-up of at least five years in order to allow for the evaluation of long-term 
efficacy and safety of DES use in specific off-label situations. Since off-label 
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indications comprise a large amount of the PCI procedures in current practice, 
having data from randomized control trials will be extremely valuable in whether 
or not to use DESs in treatment of different coronary artery disease patients on a 
case-by-case basis. 
Finally, as technology continues advance in the design of drug eluting stents, 
it is important that these stents be evaluated in studies similar to those described 
for first generation drug-eluting stents to evaluate their safety and long-term 
efficacy in different clinical scenarios. Of particular interest is the polymer-free 
drug eluting stent. The durable polymer currently found on first generation DESs 
may play a role in delaying vascular healing leading to some adverse effects in 
the vasculature. Currently, investigation of the polymer-free Biolimus A9-coated 
stent in clinical cases is taking place.2 These research efforts should continue in 
an on-going effort to make stents as safe and effective as possible. 
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